stocks Teladoc Health (NYSE: TDOC) It has pulled back from the post-pandemic peak periods this summer, but the company’s business has not stopped growing at a dizzying pace. Now that the stock has fallen to a more reasonable valuation, Baird, an investment bank, today gave it a $ 220 upgrade and target price which is 18% higher than Thursday’s closing price.
Analysts have encouraged the strong and continued uptake of Teladoc’s services throughout the coronavirus pandemic. Teladoc’s network of providers provided more than 2.8 million virtual visits in the third quarter, which was more than three times the number of visits provided during the previous year.
The massive traffic volume was driven by the new patients gaining access, and the rate of use that more than doubled year after year. Despite more healthcare providers providing in-person services during the third quarter, Teladoc reported an annual use rate 0.5% higher than the second quarter’s numbers.
While some investors are upset by the company’s decision to merge with Livongo earlier this year, the joint business is already helping Teladoc gain new customers. New customer cross-sales that occurred before the company formally completed its acquisition of Livongo at the end of October, has led Teladoc to expect at least twice as many bookings in the fourth quarter as reported in the third.
Livongo helps people manage chronic health conditions with the help of devices that track health signals and provide real-time suggestions. When Teladoc made its merger offer, Livongo’s flagship diabetes service boasted about 410,000 members representing a tiny fraction of the 34.2 million Americans with diabetes.
Avid music fanatic. Communicator. Social media expert. Award-winning bacon scholar. Alcohol fan.